EYLEA 2 mg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).¹

EYLEA 2 mg: T&E DOSING UP TO Q16, in nAMD

¹

After 3 initial monthly doses, the EYLEA 2 mg treatment interval is extended to 2 months. The treatment interval can then be further extended up to 16 weeks, using proactive T&E dosing.¹

Adapted from EYLEA 2 mg Summary of Product Characteristics.

There is no requirement for monitoring between injections.¹*

EYLEA 2 mg posology in nAMD

The recommended dose for EYLEA is 2 mg aflibercept, equivalent to 0.05 mL. EYLEA treatment is initiated with one injection per month for three consecutive doses. The treatment interval is then extended to 2 months. Based on the physician’s judgement of visual and/or anatomic outcomes, the treatment interval may be maintained at 2 months or further extended using a treat-and-extend dosing regimen, where injection intervals are increased in 2- or 4-weekly increments to maintain stable visual and/or anatomic outcomes. If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly. There is no requirement for monitoring between injections. Based on the physician’s judgement, the schedule of monitoring visits may be more frequent than the injection visits. Treatment intervals greater than 4 months or shorter than 4 weeks between injections have not been studied.¹ 

Abbreviations

AMD, age-related macular degeneration. DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. nAMD, neovascular age-related macular degeneration. Q8, 2 mg every 8 weeks. Q16, 2 mg every 16 weeks. RVO, retinal vein occlusion. T&E, treat and extend.

Footnote

*These T&E dosing schedules are for illustrative purposes only and show a hypothetical scenario where dose extension takes place at each visit. Actual T&E dosing regimens will vary by patient.

References

1. EYLEA® 40 mg/mL Summary of Product Characteristics.
2. Ohji M, et al. Adv Ther 2020;37:1173–1187.
3. Mitchell P, et al. Retina 2021;41:1911–1920.
4. Schmidt-Erfurth U, et al. Ophthalmology 2014;121:193–201.